1. MARKETS
  2. SECTOR : PHARMA & BIOTECH
  3. INDUSTRY : MAJOR PHARMACEUTICALS
  4. ASTRIA THERAPEUTICS INC
Astria Therapeutics Inc
XNAS: ATXS

Watchlist

Portfolio

Alert
Board Meeting
The next board meeting for Astria Therapeutics Inc is on 13 May 2026 for the purpose of Astria Therapeutics Inc First Quarter Earnings Results for 2026 See details


Insider Trading disclosures for Astria Therapeutics Inc

The latest disclosure was made by Michael D. Kishbauch in Astria Therapeutics Inc where a trade of 26,550 Stock Option (Right to Buy) done was reported to US exchanges on June 11, 2025.

Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company. A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).

Client Name Client Category Action Reported to Exchange Quantity Post Transaction Holding Traded % Avg. Price Value Security Type
Michael D. Kishbauch Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 11 Jun 2025 26,550 26,550 - - Stock Option (Right to Buy)
Kenneth M. Bate Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 11 Jun 2025 26,550 26,550 - - Stock Option (Right to Buy)
Gregg Anthony Lapointe Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 11 Jun 2025 26,550 26,550 - - Stock Option (Right to Buy)
Hugh M. Cole Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 11 Jun 2025 26,550 26,550 - - Stock Option (Right to Buy)
Sunil Agarwal Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 11 Jun 2025 26,550 26,550 - - Stock Option (Right to Buy)
Jonathan Violin Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 11 Jun 2025 26,550 26,550 - - Stock Option (Right to Buy)
Joanne T. Beck Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 11 Jun 2025 26,550 26,550 - - Stock Option (Right to Buy)
Frederick C. Callori Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 11 Jun 2025 26,550 26,550 - - Stock Option (Right to Buy)
Jill C. Milne Director, CEO and President Grant, award, or other acquisition of securities at price $ 0.00 per share. 21 Mar 2025 761,000 761,000 - - Stock Option (Right to Buy)
Benjamin Harshbarger Chief Legal Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 21 Mar 2025 262,500 262,500 - - Stock Option (Right to Buy)
Noah Clauser Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 21 Mar 2025 262,500 262,500 - - Stock Option (Right to Buy)
Andrew Komjathy Chief Commercial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 21 Mar 2025 225,000 225,000 - - Stock Option (Right to Buy)
Andrea Matthews Chief Business Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 21 Mar 2025 262,500 262,500 - - Stock Option (Right to Buy)
Christopher Morabito Chief Medical Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 21 Mar 2025 262,500 262,500 - - Stock Option (Right to Buy)
Michael D. Kishbauch Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 05 Jun 2024 14,100 14,100 - - Stock Option (Right to Buy)
Kenneth M. Bate Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 05 Jun 2024 14,100 14,100 - - Stock Option (Right to Buy)
Gregg Anthony Lapointe Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 05 Jun 2024 14,100 14,100 - - Stock Option (Right to Buy)
Hugh M. Cole Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 05 Jun 2024 14,100 14,100 - - Stock Option (Right to Buy)
Jonathan Violin Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 05 Jun 2024 14,100 14,100 - - Stock Option (Right to Buy)
Joanne T. Beck Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 05 Jun 2024 14,100 14,100 - - Stock Option (Right to Buy)
Frederick C. Callori Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 05 Jun 2024 14,100 14,100 - - Stock Option (Right to Buy)
Sunil Agarwal Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 08 Apr 2024 28,200 28,200 - - Stock Option (Right to Buy)
Christopher Morabito Chief Medical Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.87 per share. 01 Apr 2024 10,000 10,000 (0%) 0% 3.9 38,700 Common Stock
Christopher Morabito Chief Medical Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 01 Apr 2024 10,000 80,000 - - Stock Option (Right to Buy)
Christopher Morabito Chief Medical Officer Sale of securities on an exchange or to another person at price $ 13.59 per share. 01 Apr 2024 10,000 0 (0%) 0% 13.6 135,939 Common Stock
Morabito Christopher Chief Medical Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 08 Feb 2024 175,000 175,000 - - Stock Option (Right to Buy)
Noah Clauser Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 08 Feb 2024 175,000 175,000 - - Stock Option (Right to Buy)
Milne C. Jill Director, CEO and President Grant, award, or other acquisition of securities at price $ 0.00 per share. 08 Feb 2024 534,600 534,600 - - Stock Option (Right to Buy)
Matthews Andrea Chief Business Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 08 Feb 2024 175,000 175,000 - - Stock Option (Right to Buy)
Benjamin Harshbarger Chief Legal Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 08 Feb 2024 175,000 175,000 - - Stock Option (Right to Buy)
Andrew Komjathy Chief Commercial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 08 Feb 2024 175,000 175,000 - - Stock Option (Right to Buy)
Christopher Morabito Chief Medical Officer Sale of securities on an exchange or to another person at price $ 11.02 per share. 26 Jan 2024 800 0 (0%) 0% 11.0 8,812 Common Stock
Christopher Morabito Chief Medical Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 26 Jan 2024 800 99,200 - - Stock Option (Right to Buy)
Christopher Morabito Chief Medical Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 26 Jan 2024 9,200 90,000 - - Stock Option (Right to Buy)
Christopher Morabito Chief Medical Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.87 per share. 26 Jan 2024 9,200 9,200 (0%) 0% 3.9 35,604 Common Stock
Christopher Morabito Chief Medical Officer Sale of securities on an exchange or to another person at price $ 11.15 per share. 26 Jan 2024 9,200 0 (0%) 0% 11.1 102,552 Common Stock
Morabito Christopher Chief Medical Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.87 per share. 26 Jan 2024 800 800 (0%) 0% 3.9 3,096 Common Stock
Michael D. Kishbauch Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 02 Jun 2023 14,100 14,100 - - Stock Option (Right to Buy)
Kenneth M. Bate Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 02 Jun 2023 14,100 14,100 - - Stock Option (Right to Buy)
Gregg Anthony Lapointe Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 02 Jun 2023 14,100 14,100 - - Stock Option (Right to Buy)
Hugh M. Cole Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 02 Jun 2023 14,100 14,100 - - Stock Option (Right to Buy)
Jonathan Violin Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 02 Jun 2023 14,100 14,100 - - Stock Option (Right to Buy)
Jill C. Milne Director, CEO and President Grant, award, or other acquisition of securities at price $ 0.00 per share. 02 Jun 2023 275,000 275,000 - - Stock Option (Right to Buy)
Benjamin Harshbarger Chief Legal Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 02 Jun 2023 90,000 90,000 - - Stock Option (Right to Buy)
Noah Clauser Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 02 Jun 2023 100,000 100,000 - - Stock Option (Right to Buy)
Joanne T. Beck Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 02 Jun 2023 14,100 14,100 - - Stock Option (Right to Buy)
Andrew Komjathy Chief Commercial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 02 Jun 2023 80,000 80,000 - - Stock Option (Right to Buy)
Frederick C. Callori Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 02 Jun 2023 14,100 14,100 - - Stock Option (Right to Buy)
Andrea Matthews Chief Business Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 02 Jun 2023 60,000 60,000 - - Stock Option (Right to Buy)
Christopher Morabito Chief Medical Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 02 Jun 2023 90,000 90,000 - - Stock Option (Right to Buy)
Andrea Matthews Chief Business Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 17 Apr 2023 20,000 20,000 - - Stock Option (Right to Buy)
Michael D. Kishbauch Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 09 Jun 2022 8,333 8,333 - - Stock Option (right to buy)
Kenneth M. Bate Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 09 Jun 2022 8,333 8,333 - - Stock Option (right to buy)
Gregg Anthony Lapointe Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 09 Jun 2022 8,333 8,333 - - Stock Option (right to buy)
Hugh M. Cole Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 09 Jun 2022 8,333 8,333 - - Stock Option (right to buy)
Jonathan Violin Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 09 Jun 2022 8,333 8,333 - - Stock Option (right to buy)
Joanne T. Beck Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 09 Jun 2022 8,333 8,333 - - Stock Option (right to buy)
Frederick C. Callori Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 09 Jun 2022 8,333 8,333 - - Stock Option (right to buy)
Jill C. Milne Director, CEO and President Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Mar 2022 195,000 195,000 - - Stock Option (right to buy)
Benjamin Harshbarger Chief Legal Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Mar 2022 55,000 55,000 - - Stock Option (right to buy)
Andrew John Nichols Chief Scientific Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Mar 2022 55,000 55,000 - - Stock Option (right to buy)
Noah Clauser Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Mar 2022 55,000 55,000 - - Stock Option (right to buy)
Andrew Komjathy Chief Commercial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Mar 2022 55,000 55,000 - - Stock Option (right to buy)
Andrew Komjathy Chief Commercial Officer Purchase of securities on an exchange or from another person at price $ 6.70 per share. 19 Nov 2021 100 100 (0%) 0% 6.7 670 Common Stock
Jonathan Violin Director Other type of transaction at price $ 0.00 per share. 20 Sep 2021 263,321 263,321 (0%) 0% 0 Common Stock
Jonathan Violin Director Other type of transaction at price $ 0.00 per share. 20 Sep 2021 263,321 0 (0%) 0% 0 Common Stock
Benjamin Harshbarger Chief Legal Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 08 Jun 2021 200,000 200,000 - - Stock Option (right to buy)
Michael D. Kishbauch Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 02 Jun 2021 100,000 100,000 - - Stock Option (right to buy)
Kenneth M. Bate Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 02 Jun 2021 100,000 100,000 - - Stock Option (right to buy)
Gregg Anthony Lapointe Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 02 Jun 2021 100,000 100,000 - - Stock Option (right to buy)
Hugh M. Cole Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 02 Jun 2021 100,000 100,000 - - Stock Option (right to buy)
Jonathan Violin Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 02 Jun 2021 85,000 85,000 - - Stock Option (right to buy)
Jill C. Milne Director, CEO and President Grant, award, or other acquisition of securities at price $ 0.00 per share. 02 Jun 2021 1,400,000 1,400,000 - - Stock Option (right to buy)
Benjamin Harshbarger Senior VP, General Counsel Grant, award, or other acquisition of securities at price $ 0.00 per share. 02 Jun 2021 400,000 400,000 - - Stock Option (right to buy)
Andrew John Nichols Chief Scientific Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 02 Jun 2021 600,000 600,000 - - Stock Option (right to buy)
Noah Clauser Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 02 Jun 2021 600,000 600,000 - - Stock Option (right to buy)
Joanne T. Beck Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 02 Jun 2021 100,000 100,000 - - Stock Option (right to buy)
Andrew Komjathy Chief Commercial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 02 Jun 2021 600,000 600,000 - - Stock Option (right to buy)
Fred Callori Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 02 Jun 2021 85,000 85,000 - - Stock Option (right to buy)
Fred Callori Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Feb 2021 1,617 30,920 - - Series X Convertible Preferred Stock
Jonathan Violin Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 28 Jan 2021 15,000 15,000 - - Stock Option (Right to Buy)
Fred Callori Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 28 Jan 2021 15,000 15,000 - - Stock Option (right to buy)
Noah Clauser Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 17 Sep 2020 35,000 35,000 - - Stock Option (right to buy)
Burt A. Adelman Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 11 Jun 2020 7,500 7,500 - - Stock Option (right to buy)
Michael D. Kishbauch Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 11 Jun 2020 7,500 7,500 - - Stock Option (right to buy)
Kenneth M. Bate Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 11 Jun 2020 7,500 7,500 - - Stock Option (right to buy)
Gregg Anthony Lapointe Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 11 Jun 2020 7,500 7,500 - - Stock Option (right to buy)
Hugh M. Cole Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 11 Jun 2020 7,500 7,500 - - Stock Option (right to buy)
Joanne T. Beck Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 11 Jun 2020 7,500 7,500 - - Stock Option (right to buy)
Joanne M. Donovan CMO; SVP Clinical Development Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Feb 2020 60,000 60,000 - - Stock Option (right to buy)
Jill C. Milne Director, CEO and President Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Feb 2020 150,000 150,000 - - Stock Option (right to buy)
Andrew John Nichols Chief Scientific Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Feb 2020 60,000 60,000 - - Stock Option (right to buy)
Noah Clauser Principal Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Feb 2020 20,000 20,000 - - Stock Option (right to buy)
Andrew Komjathy Chief Commercial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Feb 2020 35,000 35,000 - - Stock Option (right to buy)
Andrew Komjathy Chief Commercial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 18 Sep 2019 44,500 44,500 - - Stock Option (right to buy)
Hugh M. Cole None Grant, award, or other acquisition of securities at price $ 0.00 per share. 26 Jul 2019 15,000 15,000 - - Stock Option (right to buy)
Burt A. Adelman None Grant, award, or other acquisition of securities at price $ 0.00 per share. 04 Jun 2019 7,500 7,500 - - Stock Option (right to buy)
Michael D. Kishbauch None Grant, award, or other acquisition of securities at price $ 0.00 per share. 04 Jun 2019 7,500 7,500 - - Stock Option (right to buy)
Kenneth M. Bate None Grant, award, or other acquisition of securities at price $ 0.00 per share. 04 Jun 2019 7,500 7,500 - - Stock Option (right to buy)
Gregg Anthony Lapointe None Grant, award, or other acquisition of securities at price $ 0.00 per share. 13 Feb 2019 12,200 12,200 - - Stock Option (right to buy)
Joanne M. Donovan CMO; SVP Clinical Development Grant, award, or other acquisition of securities at price $ 0.00 per share. 13 Feb 2019 40,000 40,000 - - Stock Option (right to buy)
Jill C. Milne Director, CEO and President Grant, award, or other acquisition of securities at price $ 0.00 per share. 13 Feb 2019 100,000 100,000 - - Stock Option (right to buy)
Deirdre A. Cunnane Chief Legal Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 13 Feb 2019 40,000 40,000 - - Stock Option (right to buy)
Andrew John Nichols Chief Scientific Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 13 Feb 2019 40,000 40,000 - - Stock Option (right to buy)
Joanne T. Beck None Grant, award, or other acquisition of securities at price $ 0.00 per share. 13 Feb 2019 15,000 15,000 - - Stock Option (right to buy)
Gregg Anthony Lapointe None Grant, award, or other acquisition of securities at price $ 0.00 per share. 03 Jan 2019 2,800 2,800 - - Stock Option (right to buy)
Joanne M. Donovan CMO; SVP Clinical Development Grant, award, or other acquisition of securities at price $ 0.00 per share. 07 Sep 2018 150,000 150,000 - - Stock Option (right to buy)
Jill C. Milne Director, CEO and President Grant, award, or other acquisition of securities at price $ 0.00 per share. 07 Sep 2018 230,000 230,000 - - Stock Option (right to buy)
Deirdre A. Cunnane Chief Legal Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 07 Sep 2018 150,000 150,000 - - Stock Option (right to buy)
Andrew John Nichols Chief Scientific Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 07 Sep 2018 150,000 150,000 - - Stock Option (right to buy)
Kenneth M. Bate None Grant, award, or other acquisition of securities at price $ 0.00 per share. 07 Jun 2018 14,000 14,000 - - Stock Option (right to buy)
Burt A. Adelman None Grant, award, or other acquisition of securities at price $ 0.00 per share. 07 Jun 2018 14,000 14,000 - - Stock Option (right to buy)
Michael D. Kishbauch None Grant, award, or other acquisition of securities at price $ 0.00 per share. 07 Jun 2018 14,000 14,000 - - Stock Option (right to buy)
Jean M. George None Grant, award, or other acquisition of securities at price $ 0.00 per share. 07 Jun 2018 14,000 14,000 - - Stock Option (right to buy)
Michael Ross None Grant, award, or other acquisition of securities at price $ 0.00 per share. 07 Jun 2018 14,000 14,000 - - Stock Option (right to buy)
Joanne M. Donovan CMO; SVP Clinical Development Grant, award, or other acquisition of securities at price $ 0.00 per share. 08 Feb 2018 100,000 100,000 - - Stock Option (right to buy)
Jill C. Milne Director, CEO and President Grant, award, or other acquisition of securities at price $ 0.00 per share. 08 Feb 2018 230,000 230,000 - - Stock Option (right to buy)
Deirdre A. Cunnane SVP, General Counsel Grant, award, or other acquisition of securities at price $ 0.00 per share. 08 Feb 2018 100,000 100,000 - - Stock Option (right to buy)
Andrew John Nichols Chief Scientific Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 08 Feb 2018 100,000 100,000 - - Stock Option (right to buy)
Edward K. Hibben Chief Business Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 08 Feb 2018 100,000 100,000 - - Stock Option (right to buy)
Kenneth M. Bate None Grant, award, or other acquisition of securities at price $ 0.00 per share. 27 Jul 2017 6,500 6,500 - - Stock Option (right to buy)
Burt A. Adelman None Grant, award, or other acquisition of securities at price $ 0.00 per share. 27 Jul 2017 6,500 6,500 - - Stock Option (right to buy)
Michael D. Kishbauch None Grant, award, or other acquisition of securities at price $ 0.00 per share. 27 Jul 2017 6,500 6,500 - - Stock Option (right to buy)
Jean M. George None Grant, award, or other acquisition of securities at price $ 0.00 per share. 27 Jul 2017 6,500 6,500 - - Stock Option (right to buy)
Michael Ross None Grant, award, or other acquisition of securities at price $ 0.00 per share. 27 Jul 2017 6,500 6,500 - - Stock Option (right to buy)
Joanne M. Donovan CMO; SVP Clinical Development Grant, award, or other acquisition of securities at price $ 0.00 per share. 09 Feb 2017 100,000 100,000 - - Stock Option (right to buy)
Jill C. Milne Director, CEO and President Grant, award, or other acquisition of securities at price $ 0.00 per share. 09 Feb 2017 200,000 200,000 - - Stock Option (right to buy)
Deirdre A. Cunnane SVP, General Counsel Grant, award, or other acquisition of securities at price $ 0.00 per share. 09 Feb 2017 100,000 100,000 - - Stock Option (right to buy)
Andrew John Nichols Chief Scientific Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 09 Feb 2017 100,000 100,000 - - Stock Option (right to buy)
Andrew John Nichols Chief Scientific Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 03 Oct 2016 13,000 13,000 - - Stock Option (right to buy)
Joanne M. Donovan CMO; SVP Clinical Development Grant, award, or other acquisition of securities at price $ 0.00 per share. 08 Sep 2016 45,000 45,000 - - Stock Option (right to buy)
Jill C. Milne Director, CEO and President Grant, award, or other acquisition of securities at price $ 0.00 per share. 08 Sep 2016 45,000 45,000 - - Stock Option (right to buy)
Rick Modi Chief Business Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 08 Sep 2016 45,000 45,000 - - Stock Option (right to buy)
Deirdre A. Cunnane SVP, General Counsel Grant, award, or other acquisition of securities at price $ 0.00 per share. 08 Sep 2016 45,000 45,000 - - Stock Option (right to buy)
Kenneth M. Bate None Grant, award, or other acquisition of securities at price $ 0.00 per share. 03 Aug 2016 6,500 6,500 - - Stock Option (right to buy)
Nicholas G. Galakatos None Grant, award, or other acquisition of securities at price $ 0.00 per share. 03 Aug 2016 6,500 6,500 - - Stock Option (right to buy)
Jean M. George None Grant, award, or other acquisition of securities at price $ 0.00 per share. 03 Aug 2016 6,500 6,500 - - Stock Option (right to buy)
Michael Ross None Grant, award, or other acquisition of securities at price $ 0.00 per share. 03 Aug 2016 6,500 6,500 - - Stock Option (right to buy)
Burt A. Adelman None Grant, award, or other acquisition of securities at price $ 0.00 per share. 05 Apr 2016 13,000 13,000 - - Stock Option (right to buy)
Michael D. Kishbauch None Grant, award, or other acquisition of securities at price $ 0.00 per share. 05 Apr 2016 13,000 13,000 - - Stock Option (right to buy)
Joanne M. Donovan Chief Medical Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 11 Feb 2016 66,000 66,000 - - Stock Option (right to buy)
Jill C. Milne Director, President and CEO Grant, award, or other acquisition of securities at price $ 0.00 per share. 11 Feb 2016 103,000 103,000 - - Stock Option (right to buy)
Ian C. Sanderson Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 11 Feb 2016 52,000 52,000 - - Stock Option (right to buy)
Rick Modi Chief Business Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 11 Feb 2016 42,000 42,000 - - Stock Option (right to buy)
Deirdre A. Cunnane SVP, General Counsel Grant, award, or other acquisition of securities at price $ 0.00 per share. 11 Feb 2016 23,000 23,000 - - Stock Option (right to buy)
Jill C. Milne Director, President and CEO Grant, award, or other acquisition of securities at price $ 0.00 per share. 17 Jul 2015 160,000 160,000 - - Stock Option (right to buy)
Kenneth M. Bate None Grant, award, or other acquisition of securities at price $ 0.00 per share. 30 Jun 2015 11,094 11,094 - - Stock Option (right to buy)
Nicholas G. Galakatos Director, Ten Percent Owner 30 Jun 2015 20,800,000 0 - - Series A Preferred Stock
Nicholas G. Galakatos Director, Ten Percent Owner Grant, award, or other acquisition of securities at price $ 0.00 per share. 30 Jun 2015 11,094 11,094 - - Stock Option (right to buy)
Nicholas G. Galakatos Director, Ten Percent Owner Purchase of securities on an exchange or from another person at price $ 0.00 per share. 30 Jun 2015 376,695 2,752,488 - - Common Stock
Nicholas G. Galakatos Director, Ten Percent Owner 30 Jun 2015 9,728,971 0 - - Series B Preferred Stock
Nicholas G. Galakatos Director, Ten Percent Owner 30 Jun 2015 757,117 2,375,793 - - Common Stock
Nicholas G. Galakatos Director, Ten Percent Owner 30 Jun 2015 1,618,676 1,618,676 - - Common Stock
Jean M. George None 30 Jun 2015 674,446 674,446 - - Common Stock
Jean M. George None 30 Jun 2015 3,910,392 0 - - Series B Preferred Stock
Jean M. George None Purchase of securities on an exchange or from another person at price $ 0.00 per share. 30 Jun 2015 12,422 90,764 - - Common Stock
Jean M. George None 30 Jun 2015 8,666,667 0 - - Series A Preferred Stock
Jean M. George None 30 Jun 2015 7,388,491 0 - - Series B Preferred Stock
Jean M. George None 30 Jun 2015 78,342 78,342 - - Common Stock
Jean M. George None 30 Jun 2015 574,979 574,979 - - Common Stock
Jean M. George None 30 Jun 2015 1,006,712 0 - - Series B Preferred Stock
Jean M. George None Purchase of securities on an exchange or from another person at price $ 0.00 per share. 30 Jun 2015 91,166 666,145 - - Common Stock
Jean M. George None Purchase of securities on an exchange or from another person at price $ 0.00 per share. 30 Jun 2015 155,188 1,133,943 - - Common Stock
Jean M. George None 30 Jun 2015 304,309 978,755 - - Common Stock
Jean M. George None Grant, award, or other acquisition of securities at price $ 0.00 per share. 30 Jun 2015 11,094 11,094 - - Stock Option (right to buy)
Michael Jirousek Chief Scientific Officer 30 Jun 2015 856,571 0 - - Series A Preferred Stock
Michael Jirousek Chief Scientific Officer 30 Jun 2015 409 246,093 - - Common Stock
Michael Jirousek Chief Scientific Officer 30 Jun 2015 66,658 245,684 - - Common Stock
Michael Jirousek Chief Scientific Officer 30 Jun 2015 5,261 0 - - Series B Preferred Stock
Michael Ross None Grant, award, or other acquisition of securities at price $ 0.00 per share. 30 Jun 2015 11,094 11,094 - - Stock Option (right to buy)
Joanne M. Donovan Chief Medical Officer 30 Jun 2015 409 409 - - Common Stock
Joanne M. Donovan Chief Medical Officer 30 Jun 2015 5,261 0 - - Series B Preferred Stock
Jill C. Milne Director, President and CEO 30 Jun 2015 66,657 245,683 - - Common Stock
Jill C. Milne Director, President and CEO 30 Jun 2015 856,548 0 - - Series A Preferred Stock
Jill C. Milne Director, President and CEO 30 Jun 2015 105,229 0 - - Series B Preferred Stock
Jill C. Milne Director, President and CEO 30 Jun 2015 8,189 253,872 - - Common Stock
Rick Modi Chief Business Officer 30 Jun 2015 52,614 0 - - Series B Preferred Stock
Rick Modi Chief Business Officer 30 Jun 2015 4,094 4,094 - - Common Stock
Ron Laufer Director, Ten Percent Owner 30 Jun 2015 1,079,115 1,079,115 - - Common Stock
Ron Laufer Director, Ten Percent Owner 30 Jun 2015 13,866,666 0 - - Series A Preferred Stock
Ron Laufer Director, Ten Percent Owner 30 Jun 2015 4,241,780 0 - - Series B Preferred Stock
Ron Laufer Director, Ten Percent Owner 30 Jun 2015 330,098 1,409,213 - - Common Stock
Ron Laufer Director, Ten Percent Owner Purchase of securities on an exchange or from another person at price $ 0.00 per share. 30 Jun 2015 223,439 1,632,652 - - Common Stock
Ron Laufer Director, Ten Percent Owner Grant, award, or other acquisition of securities at price $ 0.00 per share. 30 Jun 2015 11,094 11,094 - - Stock Option (right to buy)
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc  
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges
View All The Insider Trades disclosures
Screeners based on Insider Trading and SAST parameters